108 related articles for article (PubMed ID: 12136428)
1. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity.
Kircheis R; Ostermann E; Wolschek MF; Lichtenberger C; Magin-Lachmann C; Wightman L; Kursa M; Wagner E
Cancer Gene Ther; 2002 Aug; 9(8):673-80. PubMed ID: 12136428
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment.
Kircheis R; Wightman L; Kursa M; Ostermann E; Wagner E
Gene Ther; 2002 Jun; 9(11):731-5. PubMed ID: 12032698
[TBL] [Abstract][Full Text] [Related]
3. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer.
Kursa M; Walker GF; Roessler V; Ogris M; Roedl W; Kircheis R; Wagner E
Bioconjug Chem; 2003; 14(1):222-31. PubMed ID: 12526712
[TBL] [Abstract][Full Text] [Related]
4. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application.
Kircheis R; Wightman L; Schreiber A; Robitza B; Rössler V; Kursa M; Wagner E
Gene Ther; 2001 Jan; 8(1):28-40. PubMed ID: 11402299
[TBL] [Abstract][Full Text] [Related]
5. Tissue-dependent factors affect gene delivery to tumors in vivo.
Smrekar B; Wightman L; Wolschek MF; Lichtenberger C; Ruzicka R; Ogris M; Rödl W; Kursa M; Wagner E; Kircheis R
Gene Ther; 2003 Jul; 10(13):1079-88. PubMed ID: 12808438
[TBL] [Abstract][Full Text] [Related]
6. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
[TBL] [Abstract][Full Text] [Related]
7. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo.
Kircheis R; Schüller S; Brunner S; Ogris M; Heider KH; Zauner W; Wagner E
J Gene Med; 1999; 1(2):111-20. PubMed ID: 10738575
[TBL] [Abstract][Full Text] [Related]
8. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
9. An investigation of adverse effects caused by the injection of high-dose TNFalpha-expressing adenovirus vector into established murine melanoma.
Okada Y; Okada N; Mizuguchi H; Hayakawa T; Mayumi T; Mizuno N
Gene Ther; 2003 Apr; 10(8):700-5. PubMed ID: 12692598
[TBL] [Abstract][Full Text] [Related]
10. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.
Rasmussen H; Rasmussen C; Lempicki M; Durham R; Brough D; King CR; Weichselbaum R
Cancer Gene Ther; 2002 Nov; 9(11):951-7. PubMed ID: 12386834
[TBL] [Abstract][Full Text] [Related]
11. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
[TBL] [Abstract][Full Text] [Related]
12. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
13. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.
Dufès C; Keith WN; Bilsland A; Proutski I; Uchegbu IF; Schätzlein AG
Cancer Res; 2005 Sep; 65(18):8079-84. PubMed ID: 16166279
[TBL] [Abstract][Full Text] [Related]
14. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis.
Khoury M; Louis-Plence P; Escriou V; Noel D; Largeau C; Cantos C; Scherman D; Jorgensen C; Apparailly F
Arthritis Rheum; 2006 Jun; 54(6):1867-77. PubMed ID: 16729293
[TBL] [Abstract][Full Text] [Related]
15. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.
Li P; Schwarz EM; O'Keefe RJ; Ma L; Looney RJ; Ritchlin CT; Boyce BF; Xing L
Arthritis Rheum; 2004 Jan; 50(1):265-76. PubMed ID: 14730625
[TBL] [Abstract][Full Text] [Related]
16. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models.
Streck CJ; Dickson PV; Ng CY; Zhou J; Gray JT; Nathwani AC; Davidoff AM
Clin Cancer Res; 2005 Aug; 11(16):6020-9. PubMed ID: 16115947
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.
Choi B; Hwang Y; Kwon HJ; Lee ES; Park KS; Bang D; Lee S; Sohn S
J Dermatol Sci; 2008 Nov; 52(2):87-97. PubMed ID: 18585901
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes.
Ogris M; Walker G; Blessing T; Kircheis R; Wolschek M; Wagner E
J Control Release; 2003 Aug; 91(1-2):173-81. PubMed ID: 12932649
[TBL] [Abstract][Full Text] [Related]
20. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA.
Koppu S; Oh YJ; Edrada-Ebel R; Blatchford DR; Tetley L; Tate RJ; Dufès C
J Control Release; 2010 Apr; 143(2):215-21. PubMed ID: 19944722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
